Listen now | Finding the Mechanisms and the Basis for Potential Cures

US President Donald Trump is taking a wrecking ball to science and to international institutions. The global research community must take a stand against these attacks.

Analysis of large-scale CRISPR screening data, combined with experiments in patient-derived tumour organoid models, identifies PELO as a potential therapeutic target in chromosomal 9p21.3-deleted canc...

Analysis of large-scale CRISPR screening data, combined with experiments in patient-derived tumour organoid models, identifies PELO as a potential therapeutic target in chromosomal 9p21.3-deleted canc...

The move halts a large slice of money for most universities and research institutions virtually overnight, imperiling vital research in everything from cancer to heart disease.

Move to cut indirect cost rate to 15% could cost universities billions of dollars

NIH Funding Opportunities and Notices in the NIH Guide for Grants and Contracts: Supplemental Guidance to the 2024 NIH Grants Policy Statement: Indirect Cost Rates NOT-OD-25-068. OD

The American Association for Cancer Research (AACR) is increasingly concerned about the numerous executive orders and policy proposals that the new administration has issued during the first two weeks...

The adage goes, ‘When you hear hoofbeats, think of horses, not zebras’. However, placing less emphasis on ‘zebras’ – both in the clinical and research space – can prevent many rare cancers from being ...

The functional impact of somatic mutations in cancer genes is determined by pooled Perturb-seq.

An optical pooled cell profiling platform (PERISCOPE) based on Cell Painting and optical sequencing of molecular barcodes was used to develop the first unbiased genome-wide morphology-based perturbati...

Pediatric solid tumors are a leading cause of childhood disease mortality. In this work, we examined germline structural variants (SVs) as risk factors for pediatric extracranial solid tumors using ge...

Ellrott et al. provide a means to assign patient samples from clinical trials and other cancer genome studies to published TCGA molecular subtypes. Applying machine learning to data from five different molecular platforms for 8,791 TCGA tumor samples, they contribute a public resource of 737 top classifier models, which can form the foundation for clinical assay development.